

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 May 2025 (22.05.2025)



(10) International Publication Number
WO 2025/106926 A1

(51) International Patent Classification:

A61K 31/395 (2006.01) A61K 31/166 (2006.01)
A61K 31/44 (2006.01) A61K 31/33 (2006.01)

(21) International Application Number:

PCT/US2024/056290

(22) International Filing Date:

15 November 2024 (15.11.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/599,959 16 November 2023 (16.11.2023) US
63/599,970 16 November 2023 (16.11.2023) US

(71) Applicant: **PRAXIS BIOTECH LLC** [US/US]; 5904
Doone Valley Ct., Austin, Texas 78731 (US).

(72) Inventors: **BELMAR, Sebastian**; c/o Merken Biotech
SpA, Av. Del Valle Norte 725, Santiago (CL). **URETA
DÍAZ, Gonzalo Andrés**; c/o Merken Biotech SpA, Av. Del
Valle Norte 725, Santiago (CL). **BERNALES, Sebastian**;
c/o Praxis Biotech LLC, 5904 Doone Valley Ct., Austin,
Texas 78731 (US). **NAYAK, Anjan Kumar**; c/o Praxis
Biotech LLC, 5904 Doone Valley Ct., Austin, Texas 78731
(US). **PANPATIL, Dayanand**; c/o Praxis Biotech LLC,
5904 Doone Valley Ct., Austin, Texas 78731 (US). **PU-
JALA, Brahmam**; c/o Praxis Biotech LLC, 5904 Doone
Valley Ct., Austin, Texas 78731 (US).

(74) Agent: **REANEY, Shannon** et al.; Morrison & Foerster
LLP, 755 Page Mill Road, Palo Alto, California 94304-1018
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

WO 2025/106926 A1

(54) Title: CONJUGATES TARGETING FIBROBLAST ACTIVATION PROTEIN AND USES THEREOF

(57) Abstract: Compounds and conjugates which modulate the Fibroblast Activation Protein (FAP) for the active delivery of various payloads (e.g., cytotoxic drugs, proteins, immunomodulators, radioactive components, metal chelating groups/chelating agents, fluorescent dyes, or contrast agents) are described. Such compositions may find use in therapy for treatment of diseases or disorders, such as cancer, inflammation or another disease characterized by overexpression of FAP.